A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer

被引：0
|
作者：
Siu, LL
Takimoto, CH
Awada, A
Moore, MJ
Piccart, M
Poulin-Costello, M
Lathia, C
Petrenciuc, O
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA
[3] Inst Jules Bordet, B-1000 Brussels, Belgium
[4] Bayer Inc, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3059
引用
收藏
页码：209S / 209S
页数：1
相关论文
共 50 条
  • [1] Phase I study to determine the safety and pharmacokinetics of BAY 43-9006 in patients with advanced refractory solid tumors.
    Hirte, H
    Moore, MJ
    Oza, AM
    Siu, LL
    Harris, H
    Maclean, M
    Petrenciuc, O
    Fiander, W
    Lathia, C
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3768S - 3768S
  • [2] Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors
    Richly, H
    Kupsch, P
    Passarge, K
    Grubert, M
    Hilger, RA
    Haase, CG
    Schwartz, B
    Scheulen, ME
    Seeber, S
    Strumberg, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 207S - 207S
  • [3] Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors
    Kupsch, P
    Passarge, K
    Richly, H
    Wiesemann, K
    Hilger, RA
    Haase, CG
    Schwartz, B
    Scheulen, ME
    Seeber, S
    Strumberg, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 209S - 209S
  • [4] Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC)
    Nagaiah, G.
    Fu, P.
    Wasman, J. K.
    Cooney, M. M.
    Mooney, C.
    Afshin, D.
    Lavertu, P.
    Bokar, J.
    Savvides, P.
    Remick, S. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Phase II randomised discontinuation study of BAY 43-9006 in patients with advanced melanoma
    Ahmad, T
    Marais, R
    Pyle, L
    James, M
    Schwartz, B
    Gore, M
    Eisen, T
    BRITISH JOURNAL OF CANCER, 2004, 91 : S8 - S8
  • [6] Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
    Richly, H
    Henning, BF
    Kupsch, P
    Passarge, K
    Grubert, M
    Hilger, RA
    Christensen, O
    Brendel, E
    Schwartz, B
    Ludwig, M
    Flashar, C
    Voigtmann, R
    Scheulen, ME
    Seeber, S
    Strumberg, D
    ANNALS OF ONCOLOGY, 2006, 17 (05) : 866 - 873
  • [7] BAY 43-9006: Early clinical data in patients with advanced solid malignancies
    Hotte, SJ
    Hirte, HW
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (25) : 2249 - 2253
  • [8] Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer
    Siu, LL
    Awada, A
    Takimoto, CH
    Piccart, M
    Schwartz, B
    Giannaris, T
    Lathia, C
    Petrenciuc, O
    Moore, MJ
    CLINICAL CANCER RESEARCH, 2006, 12 (01) : 144 - 151
  • [9] Phase I trial of BAY 43-9006 in combination with 5-fluorouracil (5-FU) and leucovorin (LCV) in patients with advanced refractory solid tumors
    Figer, A.
    Moscovici, M.
    Bulocinic, S.
    Radu, P.
    Atsmon, J.
    Shmuely, E.
    Laba, O.
    Gadish, D.
    Brendel, E.
    Schwartz, B.
    ANNALS OF ONCOLOGY, 2004, 15 : 87 - 88
  • [10] A clinical phase I and biomarker study of the Raf kinase inhibitor BAY 43-9006: preliminary evidence of activity in patients with advanced solid tumors
    Strumberg, D
    Voliotis, D
    Moeller, JG
    Hilger, RA
    Richly, H
    Beling, C
    Tewes, M
    Schleucher, N
    Scheulen, ME
    Seeber, S
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S53 - S54
12345